Cash is king in a high-interest environment

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Yesterday, the Reserve Bank of Australia raised the interest rate to 4.60%.

A 15-year high.

I took these flicks at my local cafe this morning:

Booooo… politics.

Get to the fun science stuff.

Well, dear reader, interest rates matter much more than you may think.

Why?

Because interest rates change the price investors are willing to pay for future growth.

THIS affects the capital available to small-cap healthcare companies.

AND the ability for small caps to raise money.

In a high-interest rate environment, cash becomes king.

Speculative shares have to offer better returns to compete.

(either through a lower entry price or higher upside reward).

It’s not just Australia feeling the pinch.

The US 10-year Treasury Yield is sitting around 5.2%.

The 10-year what?

The US 10-year Treasury yield is the annual return investors demand to lend money to the U.S. government for 10 years.

It is a key benchmark for long-term borrowing costs and asset valuations.

(Assets like our speculative small-cap healthcare stocks)

The movement in the 10-year U.S. Treasury is arguably a bigger market signal for healthcare companies competing for capital in a global economy.

If US government bonds yield 5%, then an investor can earn ~5% with little risk.

Suddenly, a speculative small cap promising a possible payoff has to offer a much bigger potential return.

(bigger than the 5% risk-free rate)

We’re starting to see the effects of the increase in the 10-year US Treasury play out.

I was up late last night waiting for Oura to ring the NASDAQ bell on Wall Street… 

A game-time call 24 hours before, but the IPO was delayed.

The reason?

“Market uncertainty.”

It’s never a good look when a high-profile, high-quality IPO gets pulled.

… especially the day before listing.

ALSO (annoyingly for me), it threw out my content plans for this morning. 

I had a deep dive into the wearables market all ready to go.

… and the Oura IPO was the centrepiece.

Now I have to write about boring things like interest rate hikes.

shakes fist in air

… anyways.

The cash rate going up is like a vacuum, suck for money out of the system.

BUT

The opposite is true as interest rates come down.

The markets work in cycles.

So for me, it’s about identifying high-quality companies at a discounted price.

And the discounts will come.

… especially for companies looking to raise capital.

In this type of environment, investors become price makers for capital raises.

So I’m on the hunt.

To date, I’ve identified three companies as my “Armchair Picks”:

I’m looking for a fourth.

It’s a tricky environment to navigate…

But a few things look very cheap right now.

Let’s dive in…

Alcidion Group Limited (ASX: ALC) signs a $7.5M, 3-year contract with Northern Care Alliance to deploy Miya Flow across multiple hospitals. (ALC)

🪑 Very nice deal.

(It’s always nice when you cover a stock and it lands with a material deal two days later).

Paradigm Biopharmaceuticals (ASX: PAR) enters voluntary administration and suspends trading. (PAR)

🪑  Another one bites the dust.

Vectus Biosystems (ASX: VBS) announces FDA pre-IND meeting granted for VB0004 in treating Idiopathic Pulmonary Fibrosis, with feedback expected by November 2026. (VBS)

🪑  I met the CEO, Tara, at BioShares in Queenstown.

Still very early stages, but one I’ll be watching closely.

Mayne Pharma (ASX: MYX) settles patent infringement litigation with Sun Pharma, pushing back the market entry of a generic competitor to one of its products to October 2032. (MYX)

🪑  Ligtigation win.

Telix Pharmaceuticals (ASX: TLX) secures FDA Fast Track designation for its BiPASS program, enhancing prostate cancer detection with 68 Ga-PSMA-PET imaging in pre-biopsy settings. (TLX)

INOVIQ Limited (ASX: IIQ) reports the outcome of an independent review of the company’s path to bring its ovarian cancer detection test to market. (IIQ)

🪑  After a blood sample collection and handling issue that rendered the company's clinical trial futile, the company has had to re-evaluate its path forward.

The key takeaway is that the product still needs “refinement,” and “collection protocols” must be consistent before further clinical validation. There is also a clear pathway.

Stage 1: Assay optimisation.

Stage 2: Clinical Verification.

Stage 3: Lab Validation

Stage 4: Commercialisation through Lab Developed Test.

Now targeting H1 CY2028.

Essentially an 18-month delay from where the company thought it would be this time last year.

BCAL Diagnostics (ASX: BDX) announces completion of clinical validation for its blood-based BREASTEST Version 2. Sensitivity: 80.3% & Specificity: 48.5%. (BDX)

🪑  Version 2 works across a broader population than Version 1 of the BREASTEST (Sensitivity: 90%; Specificity: 86%).

Importantly, it works for all women over 30 across breast densities (a harder-to-screen population) and has a sensitivity HIGHER than a mammogram (when looking at dense breasts).

The key question is whether mammogram + BREASTEST materially lifts sensitivity above mammography alone, without generating too many false positives to manage.

Commercial rollout will begin next month.

Cleo Diagnostics (ASX: COV) files two provisional patent applications for its ovarian cancer screening test. (COV)

🪑 Milestone ticked.

Neuren Pharmaceuticals (ASX: NEU) extends US patent protection for trofinetide to March 2041 through a new weight-banded dosing patent. (NEU)

🪑 May the cash printing machine work forever!

(Or at least until the patent runs out)

Precision Neuroscience raises US$250M Series D for brain-computer interface expansion, commercialisation. (Fierce Pharma)

🪑 Big money is pouring into the “Brain Computer Interface” sector, even for companies that haven’t secured FDA clearance yet.

My pick in the sector: Control Bionics (ASX: CBL) already has FDA approval, a product on the market, and is generating revenue.

AstraZeneca invests $2B in Summit Therapeutics, gaining a 12% equity stake and an oncology co-development alliance. (Yahoo Finance)

See you all tomorrow,

The Armchair Analyst